Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis-Results of an in vitro investigation
- PMID: 38414346
- DOI: 10.1111/myc.13710
Activity of amorolfine or ciclopirox in combination with terbinafine against pathogenic fungi in onychomycosis-Results of an in vitro investigation
Abstract
Background: Onychomycoses are difficult-to-treat fungal infections with high relapse rates. Combining oral and topical antifungal drugs is associated with higher success rates. Additive or synergistic modes of action are expected to enhance treatment success rates.
Objectives: Investigation of the combined effects of antifungal drugs in vitro with different modes of action and application on clinical isolates from mycotic nails.
Methods: Isolates of Trichophyton rubrum, Trichophyton interdigitale and Scopulariopsis brevicaulis were collected from infected toenail specimens of patients with onychomycosis. Susceptibility testing was performed in 96-well polystyrene plates using a standard stepwise microdilution protocol. Additive or synergistic activity at varying concentrations was investigated by the checkerboard method.
Results: Combining terbinafine with amorolfine tended to be more effective than terbinafine in conjunction with ciclopirox. In most combinations, additive effects were observed. Synergy was detected in combinations with involving amorolfine in S. brevicaulis. These additive and synergistic interactions indicate that combined therapy with topical amorolfine and oral terbinafine is justified. Sublimation of amorolfine (and terbinafine) may enhance the penetration in and through the nail plate, and support treatment efficacy.
Conclusions: These in vitro results support the notion that combining oral terbinafine and topical amorolfine is beneficial to patients with onychomycosis, particularly if the pathogen is a non-dermatophyte fungus such as S. brevicaulis.
Keywords: amorolfine; ciclopirox; dermatophyte; mould; onychomycosis; terbinafine.
© 2024 The Authors. Mycoses published by Wiley-VCH GmbH.
Similar articles
-
An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.Indian J Dermatol Venereol Leprol. 2007 Nov-Dec;73(6):393-6. doi: 10.4103/0378-6323.37056. Indian J Dermatol Venereol Leprol. 2007. PMID: 18032857 Clinical Trial.
-
In vitro determination of the combination of ciclopirox and terbinafine in the treatment of dermatophytosis.J Mycol Med. 2024 Mar;34(1):101464. doi: 10.1016/j.mycmed.2024.101464. Epub 2024 Feb 10. J Mycol Med. 2024. PMID: 38367460
-
Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections.Mycoses. 2015 Oct;58(10):610-9. doi: 10.1111/myc.12369. Epub 2015 Sep 3. Mycoses. 2015. PMID: 26334024
-
Onychomycosis.Clin Dermatol. 2010 Mar 4;28(2):151-9. doi: 10.1016/j.clindermatol.2009.12.006. Clin Dermatol. 2010. PMID: 20347657 Review.
-
Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis.Postepy Dermatol Alergol. 2015 Feb;32(1):40-5. doi: 10.5114/pdia.2014.40968. Epub 2015 Feb 3. Postepy Dermatol Alergol. 2015. PMID: 25821426 Free PMC article. Review.
Cited by
-
Terbinafine Resistance in Trichophyton rubrum and Trichophyton indotineae: A Literature Review.Antibiotics (Basel). 2025 May 7;14(5):472. doi: 10.3390/antibiotics14050472. Antibiotics (Basel). 2025. PMID: 40426539 Free PMC article. Review.
-
[Scopulariopsis brevicaulis : The "arsenic fungus"-a difficult-to-treat pathogen].Dermatologie (Heidelb). 2025 Jun 25. doi: 10.1007/s00105-025-05526-9. Online ahead of print. Dermatologie (Heidelb). 2025. PMID: 40560262 Review. German.
References
REFERENCES
-
- Abeck D, Haneke E, Nolting S, Reinel D. Onychomykose - Aktuelle Daten zu Epidemiologie, Erregerspektrum, Risikofaktoren sowie Beeinflussung der Lebensqualität. Deutsches Ärzteblatt. 2000;97:28-29.
-
- Sigurgeirsson B. Prognostic factors for cure following treatment of onychomycosis. J Eur Acad Dermatol Venereol. 2010;24:679-684.
-
- Mugge C, Haustein UF, Nenoff P. Causative agents of onychomycosis-a retrospective study. J Dtsch Dermatol Ges. 2006;4:218-228.
-
- Skóra M, Macura AB, Bulanda M. In vitro antifungal susceptibility of Scopulariopsis brevicaulis isolates. Med Mycol. 2014;52:723-727.
-
- Reinel D. Non-dermatophyte fungi in onychomycosis - epidemiology and consequences for clinical practice. Mycoses. 2021;64:694-700.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous